Full-Life Technologies ("Full-Life", the "Company"), a fully-integrated global radiotherapeutics company, announced the completion of a US$150 million financing package, comprised of approximately US$110 million in Series D equity and US$40 million in debt financing. Vivo Capital led the financing, joined by Full-Life's strategic partner SK Biopharmaceuticals Co., Ltd. and Chengwei Capital, HSG, Junson Capital, Yunion, Plaisance, Sky9 Capital, TSG Capital, as well as other renowned shareholders.

Proceeds from the Series D round will be used to advance the Company's clinical stage assets, including potential best-in-class[225Ac]-FL-020 for prostate cancer and potential first-in-class [225Ac]-FL-261 for multiple solid tumor indications. By year-end 2026, Full-Life expects to have three differentiated clinical stage programs, all of which emerged from its UniRDC™ discovery platform. Proceeds will also facilitate the initiation of GMP-grade 225Ac manufacturing at the Company's state-of-the-art facility in Belgium. Having isotope supply and manufacture under its complete control is a significant strategic advantage in advancing radiotherapeutics rapidly through clinical development.

"Full-Life is distinguished not only by their scientific vision, but their ability to translate it into tangible clinical and operational milestones at a global scale," said Hao Dong, Managing Director at Vivo Capital. "We are impressed by their early discovery efficiency, the strong emerging data from their lead program, and the accelerated progress of their manufacturing facility in Belgium. Leading this Series D financing reflects our conviction that Full-Life is transitioning from a platform innovator to a fully integrated radiopharmaceutical company, and we are excited to support their next phase of value creation."  

"This financing reflects the significant value we have created over the past four years, evolving from a platform builder to a clinical-stage company," said Julie Wu, President and Chief Financial Officer of Full-Life. "With the strong momentum from our lead asset, and the rapid advancement of our pipeline assets, this funding will accelerate our transition toward late-stage development and ensure our Belgium GMP facility is fully operational to support global 225Ac commercial supply."

With completion of this round, Full-Life has secured nearly US$350 million funding since its inception in 2021, including equity financing and debt financing.